Abstract
Background/Aims Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. Methods Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free days was also compared between the 2 groups. Results A total of 46 patients were enrolled in this study. Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). Adverse events occurred in 2 patients. They were mild in severity. Conclusions Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. Further large-scale studies are required to validate our findings. (J Neurogastroenterol Motil 2023;29:58-64).
Original language | English |
---|---|
Pages (from-to) | 58-64 |
Number of pages | 7 |
Journal | Journal of Neurogastroenterology and Motility |
Volume | 29 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2023 |
Bibliographical note
Funding Information:Financial support: This study was funded in full by HK inno. N Corp, Seoul, Korea (Study No. KCAB_002).
Publisher Copyright:
© 2023 The Korean Society of Neurogastroenterology and Motility.
Keywords
- Gastroesophageal reflux
- Heartburn
- Potassium channel blockers
- Proton pump inhibitors
- Sleep wake disorders